Pay in 4 interest-free payments of $6.35 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Cardiovascular disease, type 2 diabetes, certain cancers, liver disease, kidney disease, joint destruction, and reduced life expectancy all link directly to excess body weight
Non-cirrhotic metabolic dysfunctionassociated steatohepatitis (MASH) with moderate to advanced liver fibrosis maintenance dose: 2.4 mg injected once weekly
Advanced-phase studies (Phase 3 and 4) continue to support its core applications in diabetes and obesity, but early research into its use for neurodegenerative and liver-related disorders presents opportunities for future market growth
.webp?width=900&height=1201&name=Semaglutide%20Image%202_900x1200%20(without%20phone).webp)
The overall benefit of metabolic-targeted therapies for MASLD is appealing, as these agents might also reduce other cardiometabolic risk factors that contribute to cardiovascular disease, which is the leading cause of death in patients with MASLD
Clients frequently find themselves regaining control over cravings and portion sizes while under semaglutide treatment
